<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120167">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538498</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-08-309</org_study_id>
    <nct_id>NCT01538498</nct_id>
  </id_info>
  <brief_title>Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer</brief_title>
  <official_title>A Clinical Trial to Develop a Peritoneal Carcinomatosis Index (PCI) in Ovarian</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <brief_summary>
    <textblock>
      -  Primary objectives: To develop peritoneal carcinomatosis index (PCI) for ovarian
           cancer, tubal cancer and primary peritoneal cancer that can represent perioperative
           intraperitoneal tumor burden objectively

        -  Secondary objectives: To establish the relationship and find out clinical significance
           between PCI, tumor location and tumor characteristics
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with primary ovarian cancer

        -  Informed consent

        -  Digital photography &amp; Checking PCI (tumor size, number, and Characteristics)

        -  Postoperative surveillance(tumor marker, image and physical examination)

             1. Developing the best fitting PCI model to reflect recurrence-free survival and
                overall survival

                  -  Selection of items

                  -  Weighting by items and tumor characteristics

             2. Analysis of prognostic impact of PCI compared to conventional staging system (FIGO
                stage) for ovarian cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Devleopment for the peritoneal carcinomatosis index (PCI)</measure>
    <time_frame>55 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">134</enrollment>
  <condition>Ovarian Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        -  primary ovarian cancer

          -  non-neoadjuvant

          -  Debulking operation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Preoperative clinical diagnosis of ovarian cancer, tubal cancer, and primary
             peritoneal carcinoma (all stage)

          2. Available preoperative image study (CT and/or MRI and/or PET)

          3. Patients who gave a written informed consent

          4. Patients must be surgical candidate considering medical and psychological condition

        Exclusion Criteria:

          -  Patients who refuse to participate or want to withdraw at anytime.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>February 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Sang-Yoon Park</investigator_full_name>
    <investigator_title>Chief, Center for Uterine Cancer</investigator_title>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>Ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
